Anavex Life Sciences Corp (AVXL)

[RedShoulder]

From the European Patent Office: ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS:

The first group, known as the Aneuploidy group, comprises disorders caused by an abnormal number of chromosomes. The primary example in this group is Down’s syndrome.



The second group consists of disorders chromosomal micro-deletions, such as the deletion of a chromosomal region. Examples in this group are William’s Beuren syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velo-cardio-facial syndrome.



The third group consists of disorders having a single gene defect. Examples in this group are ATR-X syndrome, Barth syndrome, Fragile X- syndrome, ICF syndrome, Neurofibromatosis, Rett syndrome, and Smith-Lemli-Opitz syndrome.



The last group is believed to be caused by a combination of genetic, environmental, and epigenetic factors. Examples in this group are addictive disorders, ADHD, anxiety disorders, Asperger’s syndrome, autistic disorders, depression, dyslexia, eating disorders, epilepsy, infantile spasms, fetal alcohol syndrome, hydrocephalus, manic depressive illness, mental retardation, schizophrenia, spina bifida, and Tourette’s syndrome.

Thanks Granite for this very informative post.

In the second group Anavex has Angelman Syndrome to be treated with A2-73 in the pipeline.

In the third group Anavex has Rett Syndrome and Fragile X both treated with A2-73 in the pipeline.

In the fourth group Anavex has Depression to be treated with A1-41 and Infantile Spasms to be treated with A2-73 in the pipeline.

Now the question is how many of these other rare 'Genetic Neurodevelopmental Disorders' can be treated with various drugs in the Anavex drug portfolio? I suspect more than a few.